NCT05704114View on ClinicalTrials.gov

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

May 1, 2022

Conditions
Acne VulgarisPost Inflammatory HyperpigmentationPost Inflammatory Pigmentation ChangeErythemaSkin Scarring
Interventions
DRUG

Tazarotene 0.045% Lotion

Daily topical use of tazarotene for 16 weeks.

Trial Locations (1)

02116

The Dermatology Institute of Boston, Boston

All Listed Sponsors
lead

Dr. Emmy Graber

OTHER

NCT05704114 - Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne | Biotech Hunter | Biotech Hunter